Trial continues after patient death: French heartmaker

March 4, 2014

French biomedical firm Carmat said Tuesday it would implant its experimental artificial heart into another three people, as planned, after the first recipient died.

In an email to AFP, the company said it was too soon to draw conclusions about the device's efficacy.

A 76-year-old recipient died over the weekend, 75 days after receiving the gadget, whose trials are being closely followed by French investors.

"It is premature to draw conclusions based on the outcomes from a single patient," said the the firm, whose stock was suspended at its own request on Tuesday.

"Carmat does not intend announcing the results of this trial until the implants and 30-day followup of all four intended four patients are complete."

The septuagenarian with terminal was one of four people, all with end-stage , selected for the experiment.

The trial would be considered a success if each of the four survive for at least a month.

Artificial hearts have been in use for many years as a temporary fix for patients with chronic heart problems.

Unlike these mostly synthetic pumps, the Carmat product aims to provide a longer-term solution—up to five years—to bridge the wait for a and enabling hospitalised patients to go back home and even resume work.

The device, a self-contained unit implanted in a patient's chest, is a mix of synthetic materials and animal tissue, and seeks to mimic the form and function of an actual human .

Nearly 100,000 people in Europe and the United States are in need of a , according to Carmat.

Explore further: FDA OKs HeartWare device for transplant patients

Related Stories

French firm starts human trials of artificial heart

December 20, 2013

French biomedical firm Carmat said on Friday it had begun the first human trial of its prototype artificial heart, which aims at overcoming shortages of organs available for transplant.

Recommended for you

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.